Sol-Gel Technologies Change in Accounts Receivable 2016-2024 | SLGL
Sol-Gel Technologies change in accounts receivable from 2016 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Sol-Gel Technologies Annual Change in Accounts Receivable
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$N/A |
| 2020 |
$2 |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.016B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
